{"id":14943,"date":"2020-05-21T15:02:07","date_gmt":"2020-05-21T13:02:07","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=14943"},"modified":"2020-05-21T15:02:09","modified_gmt":"2020-05-21T13:02:09","slug":"un-nou-estudi-determinara-leficacia-de-la-ivermectina-per-reduir-la-transmissio-de-la-covid-19","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/un-nou-estudi-determinara-leficacia-de-la-ivermectina-per-reduir-la-transmissio-de-la-covid-19\/","title":{"rendered":"Un nou estudi determinar\u00e0 l&#8217;efic\u00e0cia de la ivermectina per reduir la transmissi\u00f3 de la COVID-19"},"content":{"rendered":"<p>Un cop m\u00e9s, l&#8217;<a href=\"https:\/\/www.isglobal.org\/en\/\" target=\"_blank\" rel=\"noopener noreferrer\">Institut de Salut Global de Barcelona (ISGlobal)<\/a>&nbsp;portar\u00e0 a terme un nou assaig cl\u00ednic per tal de seguir avan\u00e7ant en la lluita contra la COVID-19. Aquest cop, i en col\u00b7laboraci\u00f3 amb la Cl\u00ednica Universitat de Navarra, l&#8217;objectiu \u00e9s <a href=\"https:\/\/www.isglobal.org\/ca\/-\/un-nuevo-estudio-evalua-el-uso-de-la-ivermectina-para-disminuir-la-transmision-de-la-covid-19\" target=\"_blank\" rel=\"noopener noreferrer\">determinar si en&nbsp;<strong>persones tractades amb ivermectina, SARS-CoV-2 desapareix m\u00e9s r\u00e0pidament<\/strong><\/a>; concretament, si aquest antiparasitari \u00e9s capa\u00e7 de reduir la c\u00e0rrega viral als 7 dies.<\/p>\n<p>El projecte, que rep el nom de&nbsp;<strong>SARS-CoV-2 Ivermectin Navarra ISGlobal Trial (SAINT)<\/strong>, s&#8217;ha impulsat amb l&#8217;objectiu d&#8217;ampliar el coneixement sobre la<strong>&nbsp;ivermectina<\/strong>. A dia d&#8217;avui, s&#8217;ha comprovat&nbsp;<strong><em>in vitro&nbsp;<\/em><\/strong>que aquest medicament:<\/p>\n<ul>\n<li>T\u00e9 un <strong>efecte antiviral<\/strong>&nbsp;contra altres virus d&#8217;ARN de cadena \u00fanica, com el dengue o la febre groga.<\/li>\n<li>T\u00e9 un <strong>paper immunomodulador<\/strong>.<\/li>\n<\/ul>\n<p>Ambdues funcions s\u00f3n rellevants ja que SARS-CoV-2 \u00e9s tamb\u00e9 un virus ARN de cadena \u00fanica i indueix una resposta immune desendre\u00e7ada.<\/p>\n<p>Recentment s&#8217;ha demostrat que <strong>la ivermectina pot inhibir la replicaci\u00f3 de SARS-CoV-2&nbsp;<em>in vitro<\/em> a molt altes dosis<\/strong>. En aquesta l\u00ednia, l&#8217;assaig cl\u00ednic co-liderat per l&#8217;ISGlobal pret\u00e9n avan\u00e7ar i estudiar-ho&nbsp;<em>in vivo<\/em>.<\/p>\n<p>Es tractar\u00e0 d&#8217;un assaig cl\u00ednic aleatoritzat que comptar\u00e0 amb la participaci\u00f3 de&nbsp;<strong>24 pacients amb malaltia lleu, menys de 48h des de la presentaci\u00f3 de s\u00edmptomes i sense factors de risc<\/strong>. Se&#8217;ls hi administrar\u00e0 una&nbsp;<strong>dosi \u00fanica&nbsp;<\/strong>en comprimits i es far\u00e0 un seguiment durant un mes a casa. En cinc ocasions durant aquest mes, es prendran mostres nasals i es controlar\u00e0 la simptomatologia.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;ISGlobal, juntament amb la Cl\u00ednica Universitat de Navarra, inicia un assaig cl\u00ednic per determinar l&#8217;efic\u00e0cia de la ivermectina per reduir la c\u00e0rrega viral de SARS-CoV-2 als 7 dies.<\/p>\n","protected":false},"author":9,"featured_media":14953,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[651,721,295,475],"new-type":[35],"class_list":["post-14943","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recerca","tag-assaigs-clinics","tag-coronavirus-ca","tag-isglobal-cat","tag-virus-ca","new-type-noticies"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/14943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=14943"}],"version-history":[{"count":6,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/14943\/revisions"}],"predecessor-version":[{"id":15139,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/14943\/revisions\/15139"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/14953"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=14943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=14943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=14943"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=14943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}